2021 market access prospects for Germany
pharmaphorum
FEBRUARY 23, 2021
Early in 2020 a law was passed in Germany which reaffirmed the ability of Gemeinsame Bundesausschuss (G-BA), the Federal Joint Committee, to require the collection of Real World Evidence (RWE) from launch for Advanced Therapy Medicinal Products (ATMPs). Such deals are not national but can be agreed at the insurer level.
Let's personalize your content